SavedAdd your journal

Journals / Güncel Retina Dergisi / 2021 / Cilt: 5 - Sayı: 2

Transcorneal Electrical Stimulation and Platelet Rich Plasma Therapies in Retinitis Pigmentosa Disease

Retinitis Pigmentosa Hastalığında Transkorneal Elektrik Stimülasyonu ve Trombositten Zengin Plazma Terapileri

Muhammed Necati DEMİR
Pages
123–130
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Presented review includes current informationes about these therapies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:There is no cure for Retinitis Pigmentosa disease today.
📊
Key Findings & Data:The main goals of these promising therapies are to slow the progression of the disease, to protect and increase visual functions.
💡
Conclusion & Impact:Presented review includes current informationes about these therapies.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

There is no cure for Retinitis Pigmentosa disease today. Recently, transcorneal electrical stimulation and platelet-rich plasma therapies have begun to take place in clinical practice during the treatment process. The main goals of these promising therapies are to slow the progression of the disease, to protect and increase visual functions. Presented review includes current informationes about these therapies.

Özet

Retinitis pigmentosa hastalığının bugün için kesin bir tedavisi bulunmamaktadır. Son zamanlarda, tedavi sürecinde transkorneal elektrik stimülasyonu ve trombositten zengin plazma terapileri klinik pratikte yer almaya başlamıştır. Umut veren bu terapilerin ana hedefleri hastalığın ilerleyişini yavaşlatmak, görme fonksiyonlarını korumak ve artırmaktır. Sunulan derleme bu terapiler hakkında güncel bilgiler içermektedir.

🔖

Cite This Article

DEMİR, M. N. (2021). Transcorneal Electrical Stimulation and Platelet Rich Plasma Therapies in Retinitis Pigmentosa Disease. Güncel Retina Dergisi, Cilt: 5 - Sayı: 2, 123–130. https://ajindex.com/articles/219674

References (12)

  1. Harton DT, Berson EI, Dryja TP. Retinitis pigmentosa. Lancet. 2006;368(9549):1795-1809. Parmeggiani F. Clinics, epidemiology and genetics of retinitis pigmentosa. Curr Genomics. 2011;12(4):236-237.
  2. Guadagni V, Novelli E, Piano I, Gargini C, Strettoi E: Pharmacological approaches to retinitis pigmentosa: a laboratory perspective. Prog Retin Eye Res. 2015;48:62-81.
  3. Gregory-Evans K, Weleber RG, Pennesi ME, Retinitis pigmentosa and allied disorders. In: Schachat AP, ed. Ryan’s Retina, 6th ed. Philadelphia: Elsevier; 2018;861. Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomized, controlled, open-label, phase 3 trial. Lancet. 2017;390(10097):849–860.
  4. Boye SE, Boye SL, Lewin AS, Hauswirth WW. A comprehensive review of retinal gene therapy. Mol. Ther. 2013;21(3):509–519.
  5. Sahel JA, Roska B. Gene therapy for blindness. Annu. Rev. Neurosci. 2013;36:467-488.
  6. Garg SJ, Federman J: Optogenetics, visual prosthesis and electrostimulation for retinal dystrophies. Curr Opin Ophthalmol. 2013;24(5):407-414.
  7. Özmert E, Arslan U. Management of retinitis pigmentosa by Wharton’s jelly derived mesenchymal stem cells: preliminary clinical results. Stem Cell Research & Therapy. 2020;11(1):25. Sheludchenko VM, Budzinskaya MV, Ronzina IA, Smirnova TV. Effectiveness of new techniques of intraocular stem cells transplantation in the treatment of retinitis pigmentosa. Vestn Oftalmol. 2019;135(5):267-271.
  8. Mills JO, Jalil A, Stanga PE. Electronic retinal implants and artificial vision: journey and present. Eye. 2017;31(10):1383–1398. Luo YHL, da Cruz L. The Argus II retinal prosthesis system. Prog Retin Eye Res. 2016;50:89–107.
  9. Stingl K, Zrenner E. Electronic approaches to restitute vision in patients with neurodegenerative diseases of the retina. Ophthalmic Res. 2013;50(4):215-220.
  10. Sieving PA, Caruso RC, Tao W, Coleman HR, Thompson DJ, Fullmer KR, Bush RA. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci USA. 2006;103(10):3896–3901.
  11. Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Moser A, Brockhurst RJ, et al. Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. Arch Ophthalmol. 2004;122(9):1297–1305.
  12. Bahrami H, Melia M, Dagnelie G. Lutein supplementation in retinitis pigme